XLO

XLO

USD

Xilio Therapeutics Inc. Common Stock

$0.685+0.018 (2.728%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$0.667

Hoch

$0.685

Tief

$0.667

Volumen

0.37M

Unternehmensfundamentaldaten

Marktkapitalisierung

35.5M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

1.25M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $0.62Aktuell $0.685Hoch $1.7

Ähnliche Nachrichten

GlobeNewswire

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living

Mehr anzeigen
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
GlobeNewswire

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash Xilio may elect to cancel unexercised Series B or Series C warrants

Mehr anzeigen
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living

Mehr anzeigen
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living

Mehr anzeigen
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering